NRXP logo

NRx Pharmaceuticals, Inc.

NRXP
Healthcare|Biotechnology|US
$2.38
+0.11 (+4.85%)
DCF Value
$0.70
Cash / Share
$0.71
Next Earnings Report
Nov 13, 2026
EPS est. -$0.21 · Revenue est. $1.3M
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Jun 2, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
Oct 30, 2026 · GlobeNewsWire
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Oct 29, 2026 · GlobeNewsWire
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
Oct 19, 2026 · GlobeNewsWire
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
Oct 15, 2026 · GlobeNewsWire
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
Sep 30, 2026 · GlobeNewsWire
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
Sep 15, 2026 · GlobeNewsWire
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
Sep 14, 2026 · GlobeNewsWire
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
Sep 11, 2026 · GlobeNewsWire
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
Sep 8, 2026 · GlobeNewsWire
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
Aug 17, 2026 · GlobeNewsWire

SEC Filings (70)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 2026DEFA14AProxy / shareholder voteDocumentIndex
Nov 5, 2026DEF 14AProxy / shareholder voteDocumentIndex
Nov 2, 20268-KMaterial eventDocumentIndex
Oct 16, 20268-KMaterial eventDocumentIndex
Oct 5, 20268-KMaterial eventDocumentIndex
Sep 16, 20268-KMaterial eventDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Aug 17, 20268-KMaterial eventDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 7, 20268-KMaterial eventDocumentIndex
Jul 22, 20268-KMaterial eventDocumentIndex
Jun 4, 20268-KMaterial eventDocumentIndex
Jun 2, 20268-KMaterial eventDocumentIndex
Jun 2, 2026424B5Offering prospectusDocumentIndex
May 22, 202625-NSEDocumentIndex
May 15, 202610-QQuarterly reportDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 24, 20268-KMaterial eventDocumentIndex
Mar 23, 202610-KAnnual reportDocumentIndex
Feb 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Feb 23, 2026ARSAnnual report to holdersDocumentIndex
Feb 23, 2026DEF 14AProxy / shareholder voteDocumentIndex
Feb 17, 20268-KMaterial eventDocumentIndex
Feb 17, 20268-KMaterial eventDocumentIndex
Feb 17, 2026424B5Offering prospectusDocumentIndex
Feb 13, 2026PRE 14AProxy / shareholder voteDocumentIndex
Feb 2, 20268-KMaterial eventDocumentIndex
Jan 16, 20268-KMaterial eventDocumentIndex
Dec 29, 20258-KMaterial eventDocumentIndex
Dec 22, 2025EFFECTDocumentIndex
Dec 22, 2025424B3Offering prospectusDocumentIndex
Dec 12, 2025S-3/AShelf registrationDocumentIndex
Nov 26, 20258-KMaterial eventDocumentIndex
Nov 21, 20258-K/AMaterial eventDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Oct 23, 20258-KMaterial eventDocumentIndex
Sep 26, 20258-KMaterial eventDocumentIndex
Sep 12, 20258-KMaterial eventDocumentIndex
Sep 8, 20258-KMaterial eventDocumentIndex
Aug 21, 2025SC 13GPassive 5%+ stakeDocumentIndex